Issuer directory · Biotechnology
Biotechnology: private offerings on SEC Form D.
832 issuers in this group filed a Form D since 2024, reported at least $1 million sold, and either raised from ten or more investors or amended the notice at least once. Ranked by the amount reported sold on the newest notice, 100 to a page. The platform column names the AltStreet-reviewed platform an issuer belongs to; "direct" means none is on record.
| Issuer | Reported sold | Investors | Exemption | Newest notice | Filings | Platform |
|---|---|---|---|---|---|---|
| Neuralink Corp. | $649.0M | 49 | 506(b) | Jun 12, 2025 | 1 | direct |
| Denali Therapeutics Inc. | $499.7M | 11 | 506(b) | Mar 1, 2024 | 1 | direct |
| Neumora Therapeutics, Inc. | $474.4M | 124 | 506(b) | Jan 3, 2023 | 1 | direct |
| Treeline Biosciences, Inc. | $421.8M | 43 | 506(b) | Oct 17, 2024 | 1 | direct |
| Avidity Biosciences, Inc. | $400.2M | 45 | 506(b) | Mar 19, 2024 | 1 | direct |
| Avenzo Therapeutics, Inc. | $385.9M | 22 | 506(b) | Nov 20, 2024 | 3 | direct |
| Kriya Therapeutics, Inc. | $361.8M | 29 | 506(b) | Jul 27, 2023 | 2 | direct |
| Areteia Therapeutics, Inc. | $360.0M | 16 | 506(b) | Feb 21, 2025 | 3 | direct |
| LISATA THERAPEUTICS, INC. | $351.9M | 20 | 506(b) | Oct 2, 2026 | 1 | direct |
| Eikon Therapeutics, Inc. | $350.7M | 27 | 506(b) | Feb 28, 2025 | 1 | direct |
| Crinetics Pharmaceuticals, Inc. | $350.0M | 36 | 506(b) | Mar 11, 2024 | 1 | direct |
| Sensei Biotherapeutics, Inc. | $348.9M | 104 | 506(b) | Mar 4, 2026 | 1 | direct |
| Arsenal Biosciences, Inc. | $325.4M | 26 | 506(b) | Sep 4, 2024 | 1 | direct |
| GRAIL, Inc. | $325.0M | 17 | 506(b) | Nov 7, 2025 | 1 | direct |
| Galecto, Inc. | $285.0M | 48 | 506(b) | Nov 21, 2025 | 1 | direct |
| Pathos AI, Inc. | $283.0M | 11 | 506(b) | May 1, 2025 | 1 | direct |
| Entera Bio Ltd. | $275.0M | 53 | 506(b) | Aug 12, 2026 | 1 | direct |
| Cardurion Pharmaceuticals, Inc. | $260.4M | 19 | 506(b) | Jul 24, 2024 | 1 | direct |
| RECODE THERAPEUTICS, INC. | $259.8M | 28 | 506(b) | Sep 28, 2023 | 4 | direct |
| Rhodenergy An Environmental Co Corp | $250.0M | 0 | 506(c) | Jan 15, 2026 | 1 | direct |
| Zai Lab Ltd | $249.9M | 25 | 506(b) | Nov 9, 2026 | 1 | direct |
| Cidara Therapeutics, Inc. | $240.0M | 7 | 506(b) | May 6, 2024 | 1 | direct |
| Summit Therapeutics Inc. | $235.0M | 17 | 506(b) | Sep 26, 2024 | 1 | direct |
| Seaport Therapeutics, Inc. | $225.9M | 33 | 506(b) | Oct 31, 2024 | 1 | direct |
| Genesis Therapeutics, Inc. | $224.0M | 50 | 506(b) | Aug 25, 2023 | 1 | direct |
| AdvanCell, Inc. | $218.3M | 41 | 506(b) | Jul 16, 2026 | 1 | direct |
| Metsera, Inc. | $215.0M | 38 | 506(b) | Nov 20, 2024 | 1 | direct |
| Odyssey Therapeutics, Inc. | $214.0M | 55 | 506(b) | Dec 4, 2025 | 1 | direct |
| Gossamer Bio, Inc. | $212.1M | 70 | 506(b) | Aug 7, 2023 | 1 | direct |
| Aeglea BioTherapeutics, Inc. | $210.0M | 41 | 506(b) | Jul 6, 2023 | 1 | direct |
| Zenas BioPharma, Inc. | $200.1M | 26 | 506(b) | May 14, 2024 | 1 | direct |
| ADARx Pharmaceuticals, Inc. | $200.0M | 28 | 506(b) | Aug 10, 2023 | 1 | direct |
| IMMUNIC, INC. | $200.0M | 43 | 506(b) | Mar 4, 2026 | 1 | direct |
| TheRas, Inc. | $200.0M | 15 | 506(b) | May 15, 2024 | 1 | direct |
| Tyra Biosciences, Inc. | $200.0M | 21 | 506(b) | Feb 13, 2024 | 1 | direct |
| LUMICELL, INC. | $198.1M | 64 | 506(b) | May 6, 2025 | 1 | direct |
| BioAge Labs, Inc. | $194.4M | 32 | 506(b) | Feb 13, 2024 | 1 | direct |
| Surrozen, Inc./DE | $193.0M | 18 | 506(b) | Apr 19, 2024 | 1 | direct |
| Avalyn Pharma Inc. | $189.2M | 26 | 506(b) | Oct 10, 2023 | 1 | direct |
| MapLight Therapeutics, Inc. | $188.2M | 19 | 506(b) | Jul 28, 2025 | 1 | direct |
| Tectonic Therapeutic, Inc. | $185.0M | 29 | 506(b) | Feb 14, 2025 | 1 | direct |
| Tune Therapeutics, Inc. | $182.4M | 39 | 506(b) | Jan 24, 2025 | 1 | direct |
| Epicrispr Biotechnologies, Inc. | $176.8M | 47 | 506(b) | Aug 26, 2026 | 1 | direct |
| SAB Biotherapeutics, Inc. | $175.0M | 17 | 506(b) | Aug 5, 2025 | 1 | direct |
| Aktis Oncology, Inc. | $175.0M | 39 | 506(b) | Oct 2, 2024 | 1 | direct |
| Ollin Biosciences, Inc. | $156.2M | 32 | 506(b) | Jun 24, 2026 | 1 | direct |
| Kyverna Therapeutics, Inc. | $152.0M | 24 | 506(b) | Nov 7, 2023 | 1 | direct |
| Kura Oncology, Inc. | $150.0M | 10 | 506(b) | Feb 5, 2024 | 1 | direct |
| Cellanome, Inc. | $150.0M | 20 | 506(b) | Jan 29, 2024 | 1 | direct |
| Carmot Therapeutics Inc. | $150.0M | 25 | 506(b) | Jun 6, 2023 | 1 | direct |
| RAPT Therapeutics, Inc. | $150.0M | 20 | 506(b) | Jan 3, 2025 | 1 | direct |
| Taysha Gene Therapies, Inc. | $150.0M | 42 | 506(b) | Aug 25, 2023 | 1 | direct |
| Vascular Perfusion Solutions, Inc. | $147.0M | 21 | 506(b) | May 30, 2025 | 1 | direct |
| Syncromune, Inc. | $144.8M | 77 | 506(b) | May 11, 2026 | 3 | direct |
| Veronica Holdings, LLC | $142.3M | 72 | 506(b) | Mar 3, 2025 | 1 | direct |
| NGM Bio Holdings, Inc. | $142.0M | 26 | 506(b) | Mar 27, 2026 | 2 | direct |
| ImmPACT Bio USA Inc. | $139.9M | 15 | 506(b) | Apr 2, 2024 | 2 | direct |
| Impulse Dynamics plc | $136.5M | 11 | 506(b) | May 20, 2024 | 1 | direct |
| Chroma Medicine, Inc. | $135.0M | 21 | 506(b) | Sep 1, 2023 | 2 | direct |
| Electra Therapeutics, Inc. | $134.2M | 19 | 506(b) | Oct 30, 2025 | 1 | direct |
| Endeavor Biomedicines, Inc. | $132.6M | 32 | 506(b) | May 3, 2024 | 1 | direct |
| Jasper Therapeutics, Inc. | $132.0M | 40 | 506(b) | Aug 5, 2026 | 1 | direct |
| Avalo Therapeutics, Inc. | $130.6M | 25 | 506(b) | Apr 9, 2024 | 1 | direct |
| Cartesian Therapeutics, Inc. | $130.0M | 22 | 506(b) | Jul 17, 2024 | 1 | direct |
| Celcuity Inc. | $130.0M | 2 | 506(b) | Sep 23, 2025 | 6 | direct |
| Organogenesis Holdings Inc. | $130.0M | 2 | 506(b) | Nov 27, 2024 | 1 | direct |
| NewLimit, Inc. | $129.8M | 38 | 506(b) | May 15, 2025 | 1 | direct |
| ALUMIS INC. | $129.5M | 24 | 506(b) | Mar 11, 2024 | 1 | direct |
| Ensoma, Inc. | $129.0M | 22 | 506(b) | May 23, 2023 | 2 | direct |
| Adverum Biotechnologies, Inc. | $127.8M | 20 | 506(b) | Feb 21, 2024 | 1 | direct |
| ALZHEON, INC. | $126.3M | 76 | 506(c) | Feb 10, 2025 | 3 | direct |
| Scorpion Therapeutics, Inc. | $125.7M | 38 | 506(b) | Jul 16, 2024 | 1 | direct |
| SonoThera, Inc. | $125.5M | 22 | 506(c) | Jun 30, 2026 | 1 | direct |
| Oric Pharmaceuticals, Inc. | $125.0M | 15 | 506(b) | Jun 6, 2025 | 1 | direct |
| BigHat Biosciences, Inc. | $124.1M | 40 | 506(b) | Apr 28, 2025 | 2 | direct |
| Cambrian BioPharma Inc | $123.8M | 80 | 506(c) | Jul 15, 2026 | 1 | direct |
| Lyndra Therapeutics, Inc. | $122.7M | 16 | 506(b) | Dec 29, 2023 | 1 | direct |
| Solstice Oncology, Inc. | $121.3M | 8 | 506(b) | Mar 9, 2026 | 1 | direct |
| Abcuro, Inc. | $120.1M | 21 | 506(b) | Aug 25, 2023 | 1 | direct |
| Eliem Therapeutics, Inc. | $120.0M | 8 | 506(b) | Jul 2, 2024 | 1 | direct |
| NEURONA THERAPEUTICS, INC | $120.0M | 35 | 506(b) | Feb 13, 2024 | 1 | direct |
| VEDANTA BIOSCIENCES, INC. | $118.5M | 25 | 506(b) | Aug 5, 2024 | 2 | direct |
| ILIAD BIOTECHNOLOGIES, INC. | $115.5M | 36 | 506(b) | Feb 20, 2026 | 1 | direct |
| Quince Therapeutics, Inc. | $114.7M | 27 | 506(b) | Jun 11, 2026 | 1 | direct |
| Zura Bio Ltd | $112.5M | 19 | 506(b) | May 6, 2024 | 1 | direct |
| Elektrofi, Inc. | $112.3M | 21 | 506(b) | Oct 15, 2024 | 2 | direct |
| Rakuten Medical, Inc. | $111.5M | 26 | 506(b) | Apr 13, 2026 | 1 | direct |
| Zephyr AI, Inc. | $111.4M | 30 | 506(b) | Mar 13, 2024 | 1 | direct |
| Strand Therapeutics Inc. | $108.1M | 10 | 506(b) | Mar 17, 2026 | 1 | direct |
| Vizgen, Inc. | $107.6M | 61 | 506(b) | Oct 22, 2024 | 1 | direct |
| Jnana Therapeutics Inc. | $107.0M | 8 | 506(b) | Jan 26, 2024 | 2 | direct |
| Lycia Therapeutics, Inc. | $106.6M | 16 | 506(b) | May 23, 2024 | 1 | direct |
| Aligos Therapeutics, Inc. | $105.0M | 12 | 506(b) | Feb 28, 2025 | 1 | direct |
| Iambic Therapeutics, Inc. | $103.2M | 18 | 506(b) | Oct 12, 2023 | 1 | direct |
| Autobahn Therapeutics, Inc. | $100.8M | 22 | 506(b) | Aug 1, 2024 | 1 | direct |
| Harpoon Therapeutics, Inc. | $100.2M | 18 | 506(b) | Oct 31, 2023 | 1 | direct |
| Aadi Bioscience, Inc. | $100.0M | 17 | 506(b) | Mar 18, 2025 | 1 | direct |
| Boundless Bio, Inc. | $100.0M | 26 | 506(b) | Aug 15, 2023 | 1 | direct |
| Applied Therapeutics, Inc. | $100.0M | 31 | 506(b) | Mar 13, 2024 | 1 | direct |
| Galvanize Therapeutics, Inc. | $96.1M | 28 | 506(b) | Sep 11, 2025 | 1 | direct |
Source: SEC EDGAR Form D and D/A filings. A Form D is a notice of an exempt offering; the SEC does not review or approve the offering. Reported figures are the issuer's own. Other groups: the full directory.
